Outcomes-based, risk-sharing agreements are an option for manufacturers seeking to mitigate additional price regulation and access restrictions proposed by payers, politicians, and other stakeholders. When it comes to implementation, nearly all stakeholders continue to be somewhat skeptical of outcomes-based contracts (OBCs).
Consultants with Charles River Associates solicited ideas and opinions of payers and drug manufacturers through separate live discussions to gain a deeper understanding of how to overcome roadblocks to OBCs. In this article, we share the ideas we heard, examine the obstacles, and provide examples of how payers and manufacturers can collaborate to share risk and improve patient outcomes.
To read the article, click the link below.
Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.